 WALTHAM, Mass., Sept. 09, 2021 GLOBE NEWSWIRE -- Apellis Pharmaceuticals, Inc. Nasdaq: APLS, a global biopharmaceutical company and leader in complement, today reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy GA secondary to age-related macular degeneration AMD. GA is a leading cause of blindness that impacts more than five million people globally including one million people in the United States.1,2 Based on results from the studies, the company plans to submit a New Drug Application NDA for pegcetacoplan for GA to the U.S. Food and Drug Administration FDA in the first half of 2022. 